Ikena Oncology company info

What does Ikena Oncology do?
Ikena Oncology (NASDAQ:IKNA) focuses on discovering and developing innovative cancer treatments. With a keen interest in harnessing the body's immune system and targeted therapies to fight cancer, Ikena is dedicated to advancing a diverse pipeline of therapeutic candidates aimed at addressing unmet medical needs in oncology. Their projects span multiple stages of discovery and development, emphasizing pathways that are critical for cancer cell growth and survival. Ikena aims to provide new hope and solutions for patients struggling with cancer by pushing the boundaries of science and medicine. Their objective is to transform cancer treatment by developing more effective, safer therapies that can improve the lives of patients worldwide.
Ikena Oncology company media
Company Snapshot

Is Ikena Oncology a public or private company?

key
Ownership
Public

How many people does Ikena Oncology employ?

people
Employees
43

What sector is Ikena Oncology in?

pie chart
Sector
Health Care

Where is the head office for Ikena Oncology?

location pin
Head Office
Boston, United States

What year was Ikena Oncology founded?

founded flag
Year Founded
2016
What does Ikena Oncology specialise in?
/Cancer Therapies /Drug Discovery /Targeted Medicines /Clinical Studies /Research Innovations /Precision Oncology

What are the products and/or services of Ikena Oncology?

Overview of Ikena Oncology offerings
IK-930, a TEAD inhibitor targeting the Hippo signaling pathway in tumors.
IK-175, an AHR inhibitor designed for enhancing anti-tumor immunity.
IK-412, a novel kynurenine-degrading enzyme aiming to modulate the tumor microenvironment.
Technology platform for discovering and developing targeted oncology therapies focused on previously undruggable targets.
Collaboration with Merck to explore combination therapies in oncology, integrating their expertise in cancer treatment.

Who is in the executive team of Ikena Oncology?

Ikena Oncology leadership team
  • Dr. Mark  Manfredi Ph.D.
    Dr. Mark Manfredi Ph.D.
    President, CEO & Director
  • Dr. Jotin  Marango M.D., Ph.D.
    Dr. Jotin Marango M.D., Ph.D.
    CFO & Head of Corporate Development
  • Mr. Bob  Lally
    Mr. Bob Lally
    Senior Vice President of Finance & Operations
  • Ms. Srividya  Subramanian Esq., Ph.D.
    Ms. Srividya Subramanian Esq., Ph.D.
    VP & Deputy General Counsel
  • Ms. Samantha  Vuksanic
    Ms. Samantha Vuksanic
    Head of Human Resources
  • Mr. Jeffrey  Ecsedy Ph.D.
    Mr. Jeffrey Ecsedy Ph.D.
    Chief Development Officer
  • Mr. Navin  Parwani M.S.
    Mr. Navin Parwani M.S.
    VP & Head of Quality
  • Mr. David  Damphousse M.S.
    Mr. David Damphousse M.S.
    Senior Vice President of Clinical Development Operations